Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...

AGI is a theoretical form of AI able to solve any number of hypothetical tasks using generalized human cognitive abilities Elysse Bell is a finance and business writer for Investopedia. She writes ...

Let's be honest, we're all drama queens sometimes. Whether you're texting your bestie you're “literally dying” over the latest celebrity gossip or declaring on social media that Monday mornings are ...

Slapstick comedy is a purposefully exaggerated form of performance that can portray a cartoonish reality. In the world of slapstick, characters are constantly getting hurt, mugging their faces, ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge. Founded in 2021 as a spinoff of Alphabet AI company ...

Isomorphic Labs, a young company whose artificial intelligence technology for drug research has already landed partnerships with big pharmaceutical companies, unveiled $600 million in new financing ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.